Literature DB >> 29192132

In response to the comment by Hechler et al.: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.

Simona Stivala1, Sara Gobbato1, Laura Infanti2, Martin F Reiner3, Nicole Bonetti1, Sara C Meyer4, Giovanni G Camici1, Thomas F Lüscher1, Andreas Buser2, Juerg H Beer5,3.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29192132      PMCID： PMC5709124          DOI： 10.3324/haematol.2017.181818

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

Review 1.  Additive solutions for the storage of platelets for transfusion.

Authors:  H Gulliksson
Journal:  Transfus Med       Date:  2000-12       Impact factor: 2.019

2.  Platelet concentrates derived from buffy coat and apheresis: biochemical and functional differences.

Authors:  M Böck; S Rahrig; D Kunz; G Lutze; M U Heim
Journal:  Transfus Med       Date:  2002-10       Impact factor: 2.019

3.  Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.

Authors:  Jean-Louis H Kerkhoffs; Wim L J van Putten; Viera M J Novotny; Peter A W Te Boekhorst; Martin R Schipperus; Jaap Jan Zwaginga; Lizzy C M van Pampus; Georgine E de Greef; Marleen Luten; Peter C Huijgens; Anneke Brand; Dick J van Rhenen
Journal:  Br J Haematol       Date:  2010-05-09       Impact factor: 6.998

4.  Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.

Authors:  Karin Janetzko; Jean-Pierre Cazenave; Harald Klüter; Daniel Kientz; Martine Michel; Photis Beris; Bruno Lioure; Jan Hastka; Stephane Marblie; Veronique Mayaudon; Lily Lin; Jin-Sying Lin; Maureen G Conlan; Jocelyne Flament
Journal:  Transfusion       Date:  2005-09       Impact factor: 3.157

5.  In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system.

Authors:  L Johnson; Y S Loh; M Kwok; D C Marks
Journal:  Transfus Med       Date:  2013-03-11       Impact factor: 2.019

6.  Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti-human platelet agents.

Authors:  Brian Boylan; Michael C Berndt; Mark L Kahn; Peter J Newman
Journal:  Blood       Date:  2006-03-28       Impact factor: 22.113

7.  Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG.

Authors:  Simon X Liang; Mykola Pinkevych; Levon M Khachigian; Christopher R Parish; Miles P Davenport; Beng H Chong
Journal:  Blood       Date:  2010-06-21       Impact factor: 22.113

8.  Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation.

Authors:  S Moog; P Mangin; N Lenain; C Strassel; C Ravanat; S Schuhler; M Freund; M Santer; M Kahn; B Nieswandt; C Gachet; J P Cazenave; F Lanza
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

9.  Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.

Authors:  Jeffrey McCullough; David H Vesole; Richard J Benjamin; Sherrill J Slichter; Alvaro Pineda; Edward Snyder; Edward A Stadtmauer; Ileana Lopez-Plaza; Steven Coutre; Ronald G Strauss; Lawrence T Goodnough; Joy L Fridey; Thomas Raife; Ritchard Cable; Scott Murphy; Frank Howard; Kathryn Davis; Jin-Sying Lin; Peyton Metzel; Laurence Corash; Antonis Koutsoukos; Lily Lin; Donald H Buchholz; Maureen G Conlan
Journal:  Blood       Date:  2004-05-11       Impact factor: 22.113

Review 10.  Human platelets circulating in mice: applications for interrogating platelet function and survival, the efficacy of antiplatelet therapeutics, and the molecular basis of platelet immunological disorders.

Authors:  P J Newman; R Aster; B Boylan
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824
View more
  1 in total

1.  Amotosalen/UVA pathogen inactivation technology reduces platelet activability, induces apoptosis and accelerates clearance.

Authors:  Beatrice Hechler; Catherine Ravanat; Christian Gachet
Journal:  Haematologica       Date:  2017-12       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.